Shares of biopharmaceutical company Soleno Therapeutics, Inc. (SLNO) were in the spotlight on Monday after the company ...

The U.S. Food and Drug Administration on Wednesday approved Soleno Therapeutics' drug to treat a rare genetic disorder, making it the first treatment available for patients who experience feelings of ...

Patients with PWS admitted to the hospital with COVID-19 showed increased risk of in-hospital mortality, severe disease, and mechanical ventilation.

The Food and Drug Administration on Wednesday approved the first medicine to treat people with Prader-Willi syndrome, a rare genetic disease that causes an insatiable desire to eat. The drug ...

INDICATION VYKAT XR is indicated for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome (PWS). Contraindications Use of VYKAT XR is ...

The intense hunger from hyperphagia in Prader-Willi syndrome leads to "food preoccupations ... PWS and their families," Soleno said. The rare genetic neurodevelopmental disorder affects an ...

This rare disease, Prader-Willi syndrome, has been described in medical ... she expects payers will require a prior authorization and genetic confirmation of the disease. Soleno also aims to ...

US FDA Approves First Treatment for Rare Genetic Disorder Prader-Willi Syndrome By Sneha S K (Reuters) -The U.S. Food and Drug Administration on Wednesday approved Soleno Therapeutics' drug to ...

The United States Food and Drug Administration (US FDA) has approved VYKAT™ XR, a significant milestone as the first approved treatment for hyperphagia in Prader-Willi syndrome (PWS).